11 results about "Clonidine" patented technology

The present invention relates to liquid pharmaceutical compositions of clonidine or its pharmaceutically acceptable salts thereof. Preferably, the liquid pharmaceutical compositions are suitable for oral administration, and are stable for extended periods of time. More specifically, stable liquid pharmaceutical compositions of clonidine at concentrations of 1 μg / mL or more are provided. The present invention further relates to stable oral liquid compositions of clonidine, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by clonidine.

The present invention relates to solid pharmaceutical composition suitable for sublingual administration comprising clonidine or pharmaceutically acceptable salts thereof with at least one disintegrant and at least one diluent. The present invention also relates to process for preparing the said solid pharmaceutical composition.

The invention discloses a clonidine patch drug release system and a device thereof, and belongs to the field of medicines. The storage layer, the controlled release film layer and the pressure-sensitive adhesive layer are sequentially connected from top to bottom, the backing layer is arranged at the upper end of the storage layer, and the protective layer is arranged at the lower end of the pressure-sensitive adhesive layer. The storage layer, the controlled release film layer and the pressure-sensitive adhesive layer are positioned in the round hole, and a plurality of centrosymmetric through holes are formed around the round hole; the expansion layer is fixedly connected to the backing layer and covers the upper end of the circular hole; the expansion layer is provided with two through holes I which are mutually symmetrical and are communicated with the through hole, and the expansion layer is also provided with two through holes II which are mutually symmetrical; an annular connecting ring in sliding fit with the through hole II is arranged in the through hole II; and the connecting ring is fixedly connected with the storage layer. The pressure-sensitive adhesive layer can be effectively prevented from being attached to the same position of the skin of a patient for a long time, irritation to the skin is reduced, the storage layer, the controlled-release film layer and the pressure-sensitive adhesive layer can be effectively wrapped between the backing layer and the expansion layer after use, and pets and children are prevented from swallowing the pressure-sensitive adhesive layer.

The application discloses a sustained-release transdermal patch and a preparation process thereof, and particularly relates to the technical field of pharmaceutical preparations. The patch is a five-layer composite structure, and the key lies in that: the adhesive layer and the drug depot layer both contain ion pairs of clonidine and organic acid formed in situ under specific solvent and temperature conditions, and the formation of the ion pairs is confirmed by pH value or infrared spectrum; and specific transdermal penetration enhancers are further compounded, so that programmed controlled release is realized through the cooperation of the two layers. The preparation process adopts the sequence of forming ion pairs first and then mixing, realizes coating precision of ±2μm through slit extrusion coating combined with online thickness measurement closed-loop control, adopts gradient drying process with clear temperature zone, air speed and humidity parameters, and carries out real-time quality control based on the online near-infrared spectrum detection of the pre-established PLS regression model. The process can ensure that the patch realizes near-zero-order constant-speed release within 168h, and has the advantages of stable drug release, uniform content, stable quality and high batch consistency.

The invention discloses a sustained and controlled release transdermal patch and a preparation process thereof, and particularly relates to the technical field of pharmaceutical preparations, the patch is of a five-layer composite structure, and the patch is characterized in that an adhesive layer and a drug storage layer both contain ion pairs formed by clonidine and organic acid in situ under specific solvent and temperature conditions; the formation of the composition is confirmed through a pH value or an infrared spectrum, then a specific percutaneous penetration enhancer is compounded, and programmed controlled release is realized through double-layer synergy. The preparation process adopts a sequence of firstly forming ion pairs and then mixing, the coating precision of + / -2 microns is realized by matching slit extrusion coating with on-line thickness measurement closed-loop control, and real-time quality control is performed by adopting a gradient drying process with clear temperature zone, wind speed and humidity parameters and on-line near infrared spectrum detection based on a pre-established PLS regression model. The process disclosed by the invention can ensure that the patch realizes near-zero-level constant-speed release within 168 hours, and has the advantages of stable drug release, uniform content, stable quality and high inter-batch consistency.

The invention belongs to the technical field of new application of medicines, discloses a new application method of clonidine in treatment of noise-induced hearing loss, and aims to improve hearing loss caused by noise. Clonidine is given before noise, the hearing threshold after noise is detected through ABR, and it is found that compared with a noise group without drug administration, the ABR threshold of a mouse given with the noise group of clonidine is obviously improved on the first day (PE1) after noise. Meanwhile, ABR thresholds on the seventh day (PE7) and the fourteenth day (PE14) after noise are tracked, and the hearing threshold of a mouse in a noise group given with clonidine is still obviously lower than that of a mouse in a noise group without drug administration. And inner ear tissue pathological damage caused by noise-induced hearing loss is relieved. A confocal microscope observes that PE1, PE7 and PE14 of mouse outer hair cells of a noise group which are not administered are obviously lost, zonal synapses are obviously reduced, and the mouse outer hair cells and zonal synapses of a colon noise group are not obviously changed.

The present invention relates to liquid pharmaceutical compositions of clonidine or its pharmaceutically acceptable salts thereof. Preferably, the liquid pharmaceutical compositions are suitable for oral administration, and are stable for extended periods of time. More specifically, stable liquid pharmaceutical compositions of clonidine at concentrations of 1 μg / mL or more are provided. The present invention further relates to stable oral liquid compositions of clonidine, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by clonidine.

The present disclosure relates generally to a ready-to-use oral liquid formulation of clonidine or pharmaceutically acceptable salt thereof, as well as methods of manufacture and use.

The application prepares a hyaluronic acid-encapsulated dexmedetomidine microneedle system, which is verified by multidimensional characterization, and the microneedle system has excellent forming property, mechanical property, transdermal and drug release performance, has the characteristics of rapid effect (0.5h cumulative release 43.3%) and long-term delivery (4h cumulative release 86.5%), and has good biocompatibility, and the behavior and electrophysiology experiments confirm that the anti-haze and anti-vomiting effect is remarkable, and because the alpha 2 receptor selectivity is higher, the effect is better than that of clonidine.

The present invention relates to liquid pharmaceutical compositions of clonidine or its pharmaceutically acceptable salts thereof. Preferably, the liquid pharmaceutical compositions are suitable for oral administration, and are stable for extended periods of time. More specifically, stable liquid pharmaceutical compositions of clonidine at concentrations of 1 μg / mL or more are provided. The present invention further relates to stable oral liquid compositions of clonidine, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by clonidine.

The present disclosure relates to pharmaceutical compositions comprising azaldine and a polymer, methods of making the pharmaceutical compositions, and methods of reducing ocular redness by administering the pharmaceutical compositions wherein the azaldine is present from greater than 0.05% (w / v) to no more than 0.2% (w / v) based on the total volume of the pharmaceutical composition.